Functional and anatomic outcomes of brolucizumab in adults with neovascular age-related macular degeneration - The OCTOPUS cohort study.

Purpose: To evaluate the functional and anatomic outcomes of brolucizumab in treatment-naïve adults (≥50years) with neovascular age-related macular degeneration.

Methods: This was a single-arm, open-label, multicenter study. Patients (n=210) were treated with brolucizumab 6mg at Weeks (W) 0, 4 and 8, then every 12weeks (q12w) or 8weeks (q8w) depending on disease activity. The primary endpoint was change in the area of the CNV lesion from baseline to Week 12, as measured by OCTA. Functional and anatomic outcomes were evaluated up to Week 48.

Results: Mean age was 77.8years; 61.4% were female. CNV lesion size decreased from baseline to Week 12 by 79.3% and to W48 by 68.5%. Mean (SD) BCVA increased from baseline to Week 48 by 8.3 (12.0) letters, and disease activity was absent for 77.4% of patients at W48. There was a mean (SD) decrease from baseline in CSFT (μm) of -151μm (±134) at Week 48, with most patients (62.3%) having no retinal fluid (23.9% had IRF, 16.4% had SRF, and 11.9% had sub-RPE fluid). Confirmed intraocular inflammation occurred in 24 patients, mostly during loading, and did not compromise gains in BCVA.

Conclusions: CNV lesion size as assessed by OCTA decreased with brolucizumab, which also led to vision gains and better anatomic outcomes.